HEPATOLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=271, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799571, encodeId=d128e9957138, content=中了一篇letter，6月17日下午submit，6月18日accept with editor's comments，实际没修改什么内容，编辑让追改了格式。6月19日天按编辑要求返回，遇到周六周天没审，6月22日正式ACCEPT。啥时候能中article就好了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bae5283999, createdName=1484bf18m20暂无昵称, createdTime=Wed Jun 24 16:07:52 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925381, encodeId=fb4592538117, content=三年的工作终于以Original Article 发表了。总体来说editors和reviewers的水平很专业，比较强调临床的重要意义, 机制方面要求完整性，是消化领域非常优秀的期刊。 Submission completed (28-Jun-2020) Reject with opportunity to resubmit (26-Jul-2020) Revision 1 Submission Completed (21-Jan-2021) Accept with Revisions (11-Feb-2021) Revision 2 submission completed (15-Feb-2021) ACCEPT (18-Feb-2021) , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f765429324, createdName=ms6000001798901952, createdTime=Fri Feb 19 03:15:48 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241121, encodeId=7f3c12411213b, content=有没有最近投稿的小伙伴呀，交流一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62321965538, createdName=alkfhaf, createdTime=Fri Aug 26 10:50:41 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073276, encodeId=478410e3276e6, content=怎么好多mapk ask nfkb 泛素化一套的文章，作图风格以及套路一看就是一个实验室出来的......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/16/4324cfc7a25cfb745d30ee6ba4bbddb9.jpg, createdBy=32842126143, createdName=骨科小www, createdTime=Tue Nov 23 19:58:52 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091079, encodeId=24f110910e998, content=结果中的重要文献是在结果体现，还是在引言中描述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061123, encodeId=5b501061123fb, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：临床转化;基础医学 经验分享：肝病领域的权威杂志，可惜被国内某李姓长江玩坏了。整天在上面卖NASH和肝I/R损伤的文章，净整些NF-kb、ASK1/P38和GSK-3b通路，一个流水线出的假文章！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Sat Oct 16 22:38:56 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076077, encodeId=195c10e607712, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：回顾性临床研究 11.18投稿，12.2拒稿 附两个审稿人的审稿意见 编辑建议转投hc, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Thu Dec 02 07:24:00 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570377, encodeId=76f45e03771d, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投了一篇clinical trial 04/04/2019 Submission 04/05/2019 Selecting/Assigning Reviewers 04/08/2019 Under Review 04/09/2019 Selecting/Assigning Reviewers 04/09/2019 Under Review 04/22/2019 Reviews Returned 05/01/2019 Evaluating Reviews 05/02/2019 Reject with Transfer – HepComm 非常诡异的是，经历了一个月选审稿人又重选审稿人又under review的状态，最后的拒信居然没有外审意见，说内部编辑觉得不合适直接拒的。已写信询问。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af765089489, createdName=Cure, createdTime=Fri May 03 04:49:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996951, encodeId=b281996951de, content=去年通讯一篇，三个机制相关的大问题，慢慢解决，最终接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Tue Jul 06 23:25:38 CST 2021, time=2021-07-06, status=1, ipAttribution=)]

2019-10-10 qmac

审稿速度:1.0 | 投稿命中率:25.0
经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志

271 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=271, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799571, encodeId=d128e9957138, content=中了一篇letter，6月17日下午submit，6月18日accept with editor's comments，实际没修改什么内容，编辑让追改了格式。6月19日天按编辑要求返回，遇到周六周天没审，6月22日正式ACCEPT。啥时候能中article就好了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bae5283999, createdName=1484bf18m20暂无昵称, createdTime=Wed Jun 24 16:07:52 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925381, encodeId=fb4592538117, content=三年的工作终于以Original Article 发表了。总体来说editors和reviewers的水平很专业，比较强调临床的重要意义, 机制方面要求完整性，是消化领域非常优秀的期刊。 Submission completed (28-Jun-2020) Reject with opportunity to resubmit (26-Jul-2020) Revision 1 Submission Completed (21-Jan-2021) Accept with Revisions (11-Feb-2021) Revision 2 submission completed (15-Feb-2021) ACCEPT (18-Feb-2021) , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f765429324, createdName=ms6000001798901952, createdTime=Fri Feb 19 03:15:48 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241121, encodeId=7f3c12411213b, content=有没有最近投稿的小伙伴呀，交流一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62321965538, createdName=alkfhaf, createdTime=Fri Aug 26 10:50:41 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073276, encodeId=478410e3276e6, content=怎么好多mapk ask nfkb 泛素化一套的文章，作图风格以及套路一看就是一个实验室出来的......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/16/4324cfc7a25cfb745d30ee6ba4bbddb9.jpg, createdBy=32842126143, createdName=骨科小www, createdTime=Tue Nov 23 19:58:52 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091079, encodeId=24f110910e998, content=结果中的重要文献是在结果体现，还是在引言中描述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061123, encodeId=5b501061123fb, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：临床转化;基础医学 经验分享：肝病领域的权威杂志，可惜被国内某李姓长江玩坏了。整天在上面卖NASH和肝I/R损伤的文章，净整些NF-kb、ASK1/P38和GSK-3b通路，一个流水线出的假文章！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Sat Oct 16 22:38:56 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076077, encodeId=195c10e607712, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：回顾性临床研究 11.18投稿，12.2拒稿 附两个审稿人的审稿意见 编辑建议转投hc, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Thu Dec 02 07:24:00 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570377, encodeId=76f45e03771d, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投了一篇clinical trial 04/04/2019 Submission 04/05/2019 Selecting/Assigning Reviewers 04/08/2019 Under Review 04/09/2019 Selecting/Assigning Reviewers 04/09/2019 Under Review 04/22/2019 Reviews Returned 05/01/2019 Evaluating Reviews 05/02/2019 Reject with Transfer – HepComm 非常诡异的是，经历了一个月选审稿人又重选审稿人又under review的状态，最后的拒信居然没有外审意见，说内部编辑觉得不合适直接拒的。已写信询问。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af765089489, createdName=Cure, createdTime=Fri May 03 04:49:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996951, encodeId=b281996951de, content=去年通讯一篇，三个机制相关的大问题，慢慢解决，最终接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Tue Jul 06 23:25:38 CST 2021, time=2021-07-06, status=1, ipAttribution=)]

2020-06-24 1484bf18m20暂无昵称

中了一篇letter，6月17日下午submit，6月18日accept with editor's comments，实际没修改什么内容，编辑让追改了格式。6月19日天按编辑要求返回，遇到周六周天没审，6月22日正式ACCEPT。啥时候能中article就好了

317 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=271, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799571, encodeId=d128e9957138, content=中了一篇letter，6月17日下午submit，6月18日accept with editor's comments，实际没修改什么内容，编辑让追改了格式。6月19日天按编辑要求返回，遇到周六周天没审，6月22日正式ACCEPT。啥时候能中article就好了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bae5283999, createdName=1484bf18m20暂无昵称, createdTime=Wed Jun 24 16:07:52 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925381, encodeId=fb4592538117, content=三年的工作终于以Original Article 发表了。总体来说editors和reviewers的水平很专业，比较强调临床的重要意义, 机制方面要求完整性，是消化领域非常优秀的期刊。 Submission completed (28-Jun-2020) Reject with opportunity to resubmit (26-Jul-2020) Revision 1 Submission Completed (21-Jan-2021) Accept with Revisions (11-Feb-2021) Revision 2 submission completed (15-Feb-2021) ACCEPT (18-Feb-2021) , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f765429324, createdName=ms6000001798901952, createdTime=Fri Feb 19 03:15:48 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241121, encodeId=7f3c12411213b, content=有没有最近投稿的小伙伴呀，交流一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62321965538, createdName=alkfhaf, createdTime=Fri Aug 26 10:50:41 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073276, encodeId=478410e3276e6, content=怎么好多mapk ask nfkb 泛素化一套的文章，作图风格以及套路一看就是一个实验室出来的......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/16/4324cfc7a25cfb745d30ee6ba4bbddb9.jpg, createdBy=32842126143, createdName=骨科小www, createdTime=Tue Nov 23 19:58:52 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091079, encodeId=24f110910e998, content=结果中的重要文献是在结果体现，还是在引言中描述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061123, encodeId=5b501061123fb, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：临床转化;基础医学 经验分享：肝病领域的权威杂志，可惜被国内某李姓长江玩坏了。整天在上面卖NASH和肝I/R损伤的文章，净整些NF-kb、ASK1/P38和GSK-3b通路，一个流水线出的假文章！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Sat Oct 16 22:38:56 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076077, encodeId=195c10e607712, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：回顾性临床研究 11.18投稿，12.2拒稿 附两个审稿人的审稿意见 编辑建议转投hc, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Thu Dec 02 07:24:00 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570377, encodeId=76f45e03771d, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投了一篇clinical trial 04/04/2019 Submission 04/05/2019 Selecting/Assigning Reviewers 04/08/2019 Under Review 04/09/2019 Selecting/Assigning Reviewers 04/09/2019 Under Review 04/22/2019 Reviews Returned 05/01/2019 Evaluating Reviews 05/02/2019 Reject with Transfer – HepComm 非常诡异的是，经历了一个月选审稿人又重选审稿人又under review的状态，最后的拒信居然没有外审意见，说内部编辑觉得不合适直接拒的。已写信询问。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af765089489, createdName=Cure, createdTime=Fri May 03 04:49:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996951, encodeId=b281996951de, content=去年通讯一篇，三个机制相关的大问题，慢慢解决，最终接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Tue Jul 06 23:25:38 CST 2021, time=2021-07-06, status=1, ipAttribution=)]

2021-02-19 ms6000001798901952

三年的工作终于以Original Article 发表了。总体来说editors和reviewers的水平很专业，比较强调临床的重要意义, 机制方面要求完整性，是消化领域非常优秀的期刊。 Submission completed (28-Jun-2020) Reject with opportunity to resubmit (26-Jul-2020) Revision 1 Submission Completed (21-Jan-2021) Accept with Revisions (11-Feb-2021) Revision 2 submission completed (15-Feb-2021) ACCEPT (18-Feb-2021)

241 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=271, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799571, encodeId=d128e9957138, content=中了一篇letter，6月17日下午submit，6月18日accept with editor's comments，实际没修改什么内容，编辑让追改了格式。6月19日天按编辑要求返回，遇到周六周天没审，6月22日正式ACCEPT。啥时候能中article就好了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bae5283999, createdName=1484bf18m20暂无昵称, createdTime=Wed Jun 24 16:07:52 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925381, encodeId=fb4592538117, content=三年的工作终于以Original Article 发表了。总体来说editors和reviewers的水平很专业，比较强调临床的重要意义, 机制方面要求完整性，是消化领域非常优秀的期刊。 Submission completed (28-Jun-2020) Reject with opportunity to resubmit (26-Jul-2020) Revision 1 Submission Completed (21-Jan-2021) Accept with Revisions (11-Feb-2021) Revision 2 submission completed (15-Feb-2021) ACCEPT (18-Feb-2021) , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f765429324, createdName=ms6000001798901952, createdTime=Fri Feb 19 03:15:48 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241121, encodeId=7f3c12411213b, content=有没有最近投稿的小伙伴呀，交流一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62321965538, createdName=alkfhaf, createdTime=Fri Aug 26 10:50:41 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073276, encodeId=478410e3276e6, content=怎么好多mapk ask nfkb 泛素化一套的文章，作图风格以及套路一看就是一个实验室出来的......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/16/4324cfc7a25cfb745d30ee6ba4bbddb9.jpg, createdBy=32842126143, createdName=骨科小www, createdTime=Tue Nov 23 19:58:52 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091079, encodeId=24f110910e998, content=结果中的重要文献是在结果体现，还是在引言中描述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061123, encodeId=5b501061123fb, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：临床转化;基础医学 经验分享：肝病领域的权威杂志，可惜被国内某李姓长江玩坏了。整天在上面卖NASH和肝I/R损伤的文章，净整些NF-kb、ASK1/P38和GSK-3b通路，一个流水线出的假文章！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Sat Oct 16 22:38:56 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076077, encodeId=195c10e607712, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：回顾性临床研究 11.18投稿，12.2拒稿 附两个审稿人的审稿意见 编辑建议转投hc, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Thu Dec 02 07:24:00 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570377, encodeId=76f45e03771d, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投了一篇clinical trial 04/04/2019 Submission 04/05/2019 Selecting/Assigning Reviewers 04/08/2019 Under Review 04/09/2019 Selecting/Assigning Reviewers 04/09/2019 Under Review 04/22/2019 Reviews Returned 05/01/2019 Evaluating Reviews 05/02/2019 Reject with Transfer – HepComm 非常诡异的是，经历了一个月选审稿人又重选审稿人又under review的状态，最后的拒信居然没有外审意见，说内部编辑觉得不合适直接拒的。已写信询问。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af765089489, createdName=Cure, createdTime=Fri May 03 04:49:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996951, encodeId=b281996951de, content=去年通讯一篇，三个机制相关的大问题，慢慢解决，最终接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Tue Jul 06 23:25:38 CST 2021, time=2021-07-06, status=1, ipAttribution=)]

2022-08-26 alkfhaf

有没有最近投稿的小伙伴呀，交流一下

83 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=271, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799571, encodeId=d128e9957138, content=中了一篇letter，6月17日下午submit，6月18日accept with editor's comments，实际没修改什么内容，编辑让追改了格式。6月19日天按编辑要求返回，遇到周六周天没审，6月22日正式ACCEPT。啥时候能中article就好了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bae5283999, createdName=1484bf18m20暂无昵称, createdTime=Wed Jun 24 16:07:52 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925381, encodeId=fb4592538117, content=三年的工作终于以Original Article 发表了。总体来说editors和reviewers的水平很专业，比较强调临床的重要意义, 机制方面要求完整性，是消化领域非常优秀的期刊。 Submission completed (28-Jun-2020) Reject with opportunity to resubmit (26-Jul-2020) Revision 1 Submission Completed (21-Jan-2021) Accept with Revisions (11-Feb-2021) Revision 2 submission completed (15-Feb-2021) ACCEPT (18-Feb-2021) , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f765429324, createdName=ms6000001798901952, createdTime=Fri Feb 19 03:15:48 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241121, encodeId=7f3c12411213b, content=有没有最近投稿的小伙伴呀，交流一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62321965538, createdName=alkfhaf, createdTime=Fri Aug 26 10:50:41 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073276, encodeId=478410e3276e6, content=怎么好多mapk ask nfkb 泛素化一套的文章，作图风格以及套路一看就是一个实验室出来的......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/16/4324cfc7a25cfb745d30ee6ba4bbddb9.jpg, createdBy=32842126143, createdName=骨科小www, createdTime=Tue Nov 23 19:58:52 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091079, encodeId=24f110910e998, content=结果中的重要文献是在结果体现，还是在引言中描述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061123, encodeId=5b501061123fb, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：临床转化;基础医学 经验分享：肝病领域的权威杂志，可惜被国内某李姓长江玩坏了。整天在上面卖NASH和肝I/R损伤的文章，净整些NF-kb、ASK1/P38和GSK-3b通路，一个流水线出的假文章！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Sat Oct 16 22:38:56 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076077, encodeId=195c10e607712, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：回顾性临床研究 11.18投稿，12.2拒稿 附两个审稿人的审稿意见 编辑建议转投hc, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Thu Dec 02 07:24:00 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570377, encodeId=76f45e03771d, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投了一篇clinical trial 04/04/2019 Submission 04/05/2019 Selecting/Assigning Reviewers 04/08/2019 Under Review 04/09/2019 Selecting/Assigning Reviewers 04/09/2019 Under Review 04/22/2019 Reviews Returned 05/01/2019 Evaluating Reviews 05/02/2019 Reject with Transfer – HepComm 非常诡异的是，经历了一个月选审稿人又重选审稿人又under review的状态，最后的拒信居然没有外审意见，说内部编辑觉得不合适直接拒的。已写信询问。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af765089489, createdName=Cure, createdTime=Fri May 03 04:49:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996951, encodeId=b281996951de, content=去年通讯一篇，三个机制相关的大问题，慢慢解决，最终接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Tue Jul 06 23:25:38 CST 2021, time=2021-07-06, status=1, ipAttribution=)]

2021-11-23 骨科小www

怎么好多mapk ask nfkb 泛素化一套的文章，作图风格以及套路一看就是一个实验室出来的......

130 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=271, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799571, encodeId=d128e9957138, content=中了一篇letter，6月17日下午submit，6月18日accept with editor's comments，实际没修改什么内容，编辑让追改了格式。6月19日天按编辑要求返回，遇到周六周天没审，6月22日正式ACCEPT。啥时候能中article就好了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bae5283999, createdName=1484bf18m20暂无昵称, createdTime=Wed Jun 24 16:07:52 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925381, encodeId=fb4592538117, content=三年的工作终于以Original Article 发表了。总体来说editors和reviewers的水平很专业，比较强调临床的重要意义, 机制方面要求完整性，是消化领域非常优秀的期刊。 Submission completed (28-Jun-2020) Reject with opportunity to resubmit (26-Jul-2020) Revision 1 Submission Completed (21-Jan-2021) Accept with Revisions (11-Feb-2021) Revision 2 submission completed (15-Feb-2021) ACCEPT (18-Feb-2021) , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f765429324, createdName=ms6000001798901952, createdTime=Fri Feb 19 03:15:48 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241121, encodeId=7f3c12411213b, content=有没有最近投稿的小伙伴呀，交流一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62321965538, createdName=alkfhaf, createdTime=Fri Aug 26 10:50:41 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073276, encodeId=478410e3276e6, content=怎么好多mapk ask nfkb 泛素化一套的文章，作图风格以及套路一看就是一个实验室出来的......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/16/4324cfc7a25cfb745d30ee6ba4bbddb9.jpg, createdBy=32842126143, createdName=骨科小www, createdTime=Tue Nov 23 19:58:52 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091079, encodeId=24f110910e998, content=结果中的重要文献是在结果体现，还是在引言中描述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061123, encodeId=5b501061123fb, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：临床转化;基础医学 经验分享：肝病领域的权威杂志，可惜被国内某李姓长江玩坏了。整天在上面卖NASH和肝I/R损伤的文章，净整些NF-kb、ASK1/P38和GSK-3b通路，一个流水线出的假文章！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Sat Oct 16 22:38:56 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076077, encodeId=195c10e607712, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：回顾性临床研究 11.18投稿，12.2拒稿 附两个审稿人的审稿意见 编辑建议转投hc, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Thu Dec 02 07:24:00 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570377, encodeId=76f45e03771d, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投了一篇clinical trial 04/04/2019 Submission 04/05/2019 Selecting/Assigning Reviewers 04/08/2019 Under Review 04/09/2019 Selecting/Assigning Reviewers 04/09/2019 Under Review 04/22/2019 Reviews Returned 05/01/2019 Evaluating Reviews 05/02/2019 Reject with Transfer – HepComm 非常诡异的是，经历了一个月选审稿人又重选审稿人又under review的状态，最后的拒信居然没有外审意见，说内部编辑觉得不合适直接拒的。已写信询问。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af765089489, createdName=Cure, createdTime=Fri May 03 04:49:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996951, encodeId=b281996951de, content=去年通讯一篇，三个机制相关的大问题，慢慢解决，最终接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Tue Jul 06 23:25:38 CST 2021, time=2021-07-06, status=1, ipAttribution=)]

2021-12-27 rayms

结果中的重要文献是在结果体现，还是在引言中描述？

111 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=271, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799571, encodeId=d128e9957138, content=中了一篇letter，6月17日下午submit，6月18日accept with editor's comments，实际没修改什么内容，编辑让追改了格式。6月19日天按编辑要求返回，遇到周六周天没审，6月22日正式ACCEPT。啥时候能中article就好了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bae5283999, createdName=1484bf18m20暂无昵称, createdTime=Wed Jun 24 16:07:52 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925381, encodeId=fb4592538117, content=三年的工作终于以Original Article 发表了。总体来说editors和reviewers的水平很专业，比较强调临床的重要意义, 机制方面要求完整性，是消化领域非常优秀的期刊。 Submission completed (28-Jun-2020) Reject with opportunity to resubmit (26-Jul-2020) Revision 1 Submission Completed (21-Jan-2021) Accept with Revisions (11-Feb-2021) Revision 2 submission completed (15-Feb-2021) ACCEPT (18-Feb-2021) , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f765429324, createdName=ms6000001798901952, createdTime=Fri Feb 19 03:15:48 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241121, encodeId=7f3c12411213b, content=有没有最近投稿的小伙伴呀，交流一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62321965538, createdName=alkfhaf, createdTime=Fri Aug 26 10:50:41 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073276, encodeId=478410e3276e6, content=怎么好多mapk ask nfkb 泛素化一套的文章，作图风格以及套路一看就是一个实验室出来的......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/16/4324cfc7a25cfb745d30ee6ba4bbddb9.jpg, createdBy=32842126143, createdName=骨科小www, createdTime=Tue Nov 23 19:58:52 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091079, encodeId=24f110910e998, content=结果中的重要文献是在结果体现，还是在引言中描述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061123, encodeId=5b501061123fb, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：临床转化;基础医学 经验分享：肝病领域的权威杂志，可惜被国内某李姓长江玩坏了。整天在上面卖NASH和肝I/R损伤的文章，净整些NF-kb、ASK1/P38和GSK-3b通路，一个流水线出的假文章！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Sat Oct 16 22:38:56 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076077, encodeId=195c10e607712, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：回顾性临床研究 11.18投稿，12.2拒稿 附两个审稿人的审稿意见 编辑建议转投hc, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Thu Dec 02 07:24:00 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570377, encodeId=76f45e03771d, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投了一篇clinical trial 04/04/2019 Submission 04/05/2019 Selecting/Assigning Reviewers 04/08/2019 Under Review 04/09/2019 Selecting/Assigning Reviewers 04/09/2019 Under Review 04/22/2019 Reviews Returned 05/01/2019 Evaluating Reviews 05/02/2019 Reject with Transfer – HepComm 非常诡异的是，经历了一个月选审稿人又重选审稿人又under review的状态，最后的拒信居然没有外审意见，说内部编辑觉得不合适直接拒的。已写信询问。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af765089489, createdName=Cure, createdTime=Fri May 03 04:49:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996951, encodeId=b281996951de, content=去年通讯一篇，三个机制相关的大问题，慢慢解决，最终接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Tue Jul 06 23:25:38 CST 2021, time=2021-07-06, status=1, ipAttribution=)]

2021-10-16 心内一科

审稿速度:2.0 | 投稿命中率:5.0
偏重的研究方向：临床转化;基础医学
经验分享：肝病领域的权威杂志，可惜被国内某李姓长江玩坏了。整天在上面卖NASH和肝I/R损伤的文章，净整些NF-kb、ASK1/P38和GSK-3b通路，一个流水线出的假文章！

203 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=271, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799571, encodeId=d128e9957138, content=中了一篇letter，6月17日下午submit，6月18日accept with editor's comments，实际没修改什么内容，编辑让追改了格式。6月19日天按编辑要求返回，遇到周六周天没审，6月22日正式ACCEPT。啥时候能中article就好了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bae5283999, createdName=1484bf18m20暂无昵称, createdTime=Wed Jun 24 16:07:52 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925381, encodeId=fb4592538117, content=三年的工作终于以Original Article 发表了。总体来说editors和reviewers的水平很专业，比较强调临床的重要意义, 机制方面要求完整性，是消化领域非常优秀的期刊。 Submission completed (28-Jun-2020) Reject with opportunity to resubmit (26-Jul-2020) Revision 1 Submission Completed (21-Jan-2021) Accept with Revisions (11-Feb-2021) Revision 2 submission completed (15-Feb-2021) ACCEPT (18-Feb-2021) , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f765429324, createdName=ms6000001798901952, createdTime=Fri Feb 19 03:15:48 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241121, encodeId=7f3c12411213b, content=有没有最近投稿的小伙伴呀，交流一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62321965538, createdName=alkfhaf, createdTime=Fri Aug 26 10:50:41 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073276, encodeId=478410e3276e6, content=怎么好多mapk ask nfkb 泛素化一套的文章，作图风格以及套路一看就是一个实验室出来的......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/16/4324cfc7a25cfb745d30ee6ba4bbddb9.jpg, createdBy=32842126143, createdName=骨科小www, createdTime=Tue Nov 23 19:58:52 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091079, encodeId=24f110910e998, content=结果中的重要文献是在结果体现，还是在引言中描述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061123, encodeId=5b501061123fb, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：临床转化;基础医学 经验分享：肝病领域的权威杂志，可惜被国内某李姓长江玩坏了。整天在上面卖NASH和肝I/R损伤的文章，净整些NF-kb、ASK1/P38和GSK-3b通路，一个流水线出的假文章！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Sat Oct 16 22:38:56 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076077, encodeId=195c10e607712, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：回顾性临床研究 11.18投稿，12.2拒稿 附两个审稿人的审稿意见 编辑建议转投hc, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Thu Dec 02 07:24:00 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570377, encodeId=76f45e03771d, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投了一篇clinical trial 04/04/2019 Submission 04/05/2019 Selecting/Assigning Reviewers 04/08/2019 Under Review 04/09/2019 Selecting/Assigning Reviewers 04/09/2019 Under Review 04/22/2019 Reviews Returned 05/01/2019 Evaluating Reviews 05/02/2019 Reject with Transfer – HepComm 非常诡异的是，经历了一个月选审稿人又重选审稿人又under review的状态，最后的拒信居然没有外审意见，说内部编辑觉得不合适直接拒的。已写信询问。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af765089489, createdName=Cure, createdTime=Fri May 03 04:49:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996951, encodeId=b281996951de, content=去年通讯一篇，三个机制相关的大问题，慢慢解决，最终接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Tue Jul 06 23:25:38 CST 2021, time=2021-07-06, status=1, ipAttribution=)]

2021-12-02 YJJJJJ

审稿速度:1.0 | 投稿命中率:5.0
经验分享：回顾性临床研究
11.18投稿，12.2拒稿
附两个审稿人的审稿意见
编辑建议转投hc

115 0

[GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=271, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799571, encodeId=d128e9957138, content=中了一篇letter，6月17日下午submit，6月18日accept with editor's comments，实际没修改什么内容，编辑让追改了格式。6月19日天按编辑要求返回，遇到周六周天没审，6月22日正式ACCEPT。啥时候能中article就好了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bae5283999, createdName=1484bf18m20暂无昵称, createdTime=Wed Jun 24 16:07:52 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925381, encodeId=fb4592538117, content=三年的工作终于以Original Article 发表了。总体来说editors和reviewers的水平很专业，比较强调临床的重要意义, 机制方面要求完整性，是消化领域非常优秀的期刊。 Submission completed (28-Jun-2020) Reject with opportunity to resubmit (26-Jul-2020) Revision 1 Submission Completed (21-Jan-2021) Accept with Revisions (11-Feb-2021) Revision 2 submission completed (15-Feb-2021) ACCEPT (18-Feb-2021) , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f765429324, createdName=ms6000001798901952, createdTime=Fri Feb 19 03:15:48 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241121, encodeId=7f3c12411213b, content=有没有最近投稿的小伙伴呀，交流一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62321965538, createdName=alkfhaf, createdTime=Fri Aug 26 10:50:41 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073276, encodeId=478410e3276e6, content=怎么好多mapk ask nfkb 泛素化一套的文章，作图风格以及套路一看就是一个实验室出来的......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/16/4324cfc7a25cfb745d30ee6ba4bbddb9.jpg, createdBy=32842126143, createdName=骨科小www, createdTime=Tue Nov 23 19:58:52 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091079, encodeId=24f110910e998, content=结果中的重要文献是在结果体现，还是在引言中描述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061123, encodeId=5b501061123fb, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：临床转化;基础医学 经验分享：肝病领域的权威杂志，可惜被国内某李姓长江玩坏了。整天在上面卖NASH和肝I/R损伤的文章，净整些NF-kb、ASK1/P38和GSK-3b通路，一个流水线出的假文章！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Sat Oct 16 22:38:56 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076077, encodeId=195c10e607712, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：回顾性临床研究 11.18投稿，12.2拒稿 附两个审稿人的审稿意见 编辑建议转投hc, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Thu Dec 02 07:24:00 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570377, encodeId=76f45e03771d, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投了一篇clinical trial 04/04/2019 Submission 04/05/2019 Selecting/Assigning Reviewers 04/08/2019 Under Review 04/09/2019 Selecting/Assigning Reviewers 04/09/2019 Under Review 04/22/2019 Reviews Returned 05/01/2019 Evaluating Reviews 05/02/2019 Reject with Transfer – HepComm 非常诡异的是，经历了一个月选审稿人又重选审稿人又under review的状态，最后的拒信居然没有外审意见，说内部编辑觉得不合适直接拒的。已写信询问。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af765089489, createdName=Cure, createdTime=Fri May 03 04:49:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996951, encodeId=b281996951de, content=去年通讯一篇，三个机制相关的大问题，慢慢解决，最终接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Tue Jul 06 23:25:38 CST 2021, time=2021-07-06, status=1, ipAttribution=)]

2019-05-03 Cure

审稿速度:1.0 | 投稿命中率:5.0
经验分享：投了一篇clinical trial
04/04/2019 Submission
04/05/2019 Selecting/Assigning Reviewers
04/08/2019 Under Review
04/09/2019 Selecting/Assigning Reviewers
04/09/2019 Under Review
04/22/2019 Reviews Returned
05/01/2019 Evaluating Reviews
05/02/2019 Reject with Transfer – HepComm
非常诡异的是，经历了一个月选审稿人又重选审稿人又under review的状态，最后的拒信居然没有外审意见，说内部编辑觉得不合适直接拒的。已写信询问。

241 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=271, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799571, encodeId=d128e9957138, content=中了一篇letter，6月17日下午submit，6月18日accept with editor's comments，实际没修改什么内容，编辑让追改了格式。6月19日天按编辑要求返回，遇到周六周天没审，6月22日正式ACCEPT。啥时候能中article就好了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bae5283999, createdName=1484bf18m20暂无昵称, createdTime=Wed Jun 24 16:07:52 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925381, encodeId=fb4592538117, content=三年的工作终于以Original Article 发表了。总体来说editors和reviewers的水平很专业，比较强调临床的重要意义, 机制方面要求完整性，是消化领域非常优秀的期刊。 Submission completed (28-Jun-2020) Reject with opportunity to resubmit (26-Jul-2020) Revision 1 Submission Completed (21-Jan-2021) Accept with Revisions (11-Feb-2021) Revision 2 submission completed (15-Feb-2021) ACCEPT (18-Feb-2021) , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f765429324, createdName=ms6000001798901952, createdTime=Fri Feb 19 03:15:48 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241121, encodeId=7f3c12411213b, content=有没有最近投稿的小伙伴呀，交流一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62321965538, createdName=alkfhaf, createdTime=Fri Aug 26 10:50:41 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073276, encodeId=478410e3276e6, content=怎么好多mapk ask nfkb 泛素化一套的文章，作图风格以及套路一看就是一个实验室出来的......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/16/4324cfc7a25cfb745d30ee6ba4bbddb9.jpg, createdBy=32842126143, createdName=骨科小www, createdTime=Tue Nov 23 19:58:52 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091079, encodeId=24f110910e998, content=结果中的重要文献是在结果体现，还是在引言中描述？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061123, encodeId=5b501061123fb, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：临床转化;基础医学 经验分享：肝病领域的权威杂志，可惜被国内某李姓长江玩坏了。整天在上面卖NASH和肝I/R损伤的文章，净整些NF-kb、ASK1/P38和GSK-3b通路，一个流水线出的假文章！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Sat Oct 16 22:38:56 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076077, encodeId=195c10e607712, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：回顾性临床研究 11.18投稿，12.2拒稿 附两个审稿人的审稿意见 编辑建议转投hc, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Thu Dec 02 07:24:00 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570377, encodeId=76f45e03771d, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投了一篇clinical trial 04/04/2019 Submission 04/05/2019 Selecting/Assigning Reviewers 04/08/2019 Under Review 04/09/2019 Selecting/Assigning Reviewers 04/09/2019 Under Review 04/22/2019 Reviews Returned 05/01/2019 Evaluating Reviews 05/02/2019 Reject with Transfer – HepComm 非常诡异的是，经历了一个月选审稿人又重选审稿人又under review的状态，最后的拒信居然没有外审意见，说内部编辑觉得不合适直接拒的。已写信询问。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af765089489, createdName=Cure, createdTime=Fri May 03 04:49:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996951, encodeId=b281996951de, content=去年通讯一篇，三个机制相关的大问题，慢慢解决，最终接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Tue Jul 06 23:25:38 CST 2021, time=2021-07-06, status=1, ipAttribution=)]

2021-07-06 cindichaw

去年通讯一篇，三个机制相关的大问题，慢慢解决，最终接收

130 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务